ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease - Molecular Imaging Research Center
Article Dans Une Revue EBioMedicine Année : 2016

ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease

Elisabeth Werkmeister
  • Fonction : Auteur
  • PersonId : 763733
  • IdRef : 134866517
David Mann
  • Fonction : Auteur
  • PersonId : 1032492

Résumé

Although several ADAMs (A disintegrin-like and metalloproteases) have been shown to contribute to the amy-loid precursor protein (APP) metabolism, the full spectrum of metalloproteases involved in this metabolism remains to be established. Transcriptomic analyses centred on metalloprotease genes unraveled a 50% decrease in ADAM30 expression that inversely correlates with amyloid load in Alzheimer's disease brains. Accordingly, in vitro down-or up-regulation of ADAM30 expression triggered an increase/decrease in Aβ peptides levels whereas expression of a biologically inactive ADAM30 (ADAM30 mut) did not affect Aβ secretion. Proteomics/cell-based experiments showed that ADAM30-dependent regulation of APP metabolism required both cathepsin D (CTSD) activation and APP sorting to lysosomes. Accordingly, in Alzheimer-like transgenic mice, neuronal ADAM30 over-expression lowered Aβ42 secretion in neuron primary cultures, soluble Aβ42 and amyloid plaque load levels in the brain and concomitantly enhanced CTSD activity and finally rescued long term potentiation Keywords: Alzheimer APP ADAM30 Amyloid Metabolism LTP EBioMedicine 9 (2016) 278-292 Abbreviations: ADAM, A Disintegrin and Metalloproteinase Domain; APP, amyloid precursor protein; BACE, Beta-site APP cleaving enzyme 1; BSA, bovine serum albumin; CamKIIα, Ca2+/calmodulin-dependent protein kinase II alpha; COFRADIC, combined fractional diagonal chromatography; CTSD, cathepsin D; GKAP1, G kinase-anchoring protein 1; IRS4, insulin receptor substrate 4; LTP, long term potentiation; MMP, metalloproteinase; MRI, magnetic resonance imaging; PLA, proximity ligation assay; TD2, Type 2 diabetes. ⁎
Fichier principal
Vignette du fichier
letronne2016ebiomedicine.pdf (1.96 Mo) Télécharger le fichier
letronne2016ebiomedicineS1.pdf (5.67 Mo) Télécharger le fichier
letronne2016ebiomedicineS2.xlsx (29.44 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02155738 , version 1 (13-06-2019)

Identifiants

Citer

Florent Letronne, Geoffroy Laumet, Anne-Marie Ayral, Julien Chapuis, Florie Demiautte, et al.. ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease. EBioMedicine, 2016, 9, pp.278-292. ⟨10.1016/j.ebiom.2016.06.002⟩. ⟨hal-02155738⟩
313 Consultations
95 Téléchargements

Altmetric

Partager

More